Description
Moxetumomab Medication:
Lumoxiti (Moxetumomab Pasudotox Injection) is a CD22-directed cytotoxin. It is used to treat adults with hairy cell leukemia (HCL): That has come back or has not responded to last treatment, and have received minimum two other treatments, including a type of drug named purine nucleoside analog (PNA).
Dosage: The recommended lumoxiti dosage is 0.04 mg/kg administered as a 30 minute intravenous infusion on Days 1’st, 3’rd, & 5’th of each 28-day cycle. Continue moxetumomab pasudotox treatment for a maximum of six cycles, until the disease is progressive, or unacceptable toxicity occurs.
Side Effects: The most commonly reported lumoxiti side effects may include:
- Edema
- Nausea
- Fatigue
- Headache
- Pyrexia
- Constipation
- Anemia
- Diarrhea
- Infusion related reactions
Warnings and Precautions:
- Patients on moxetumomab pasudotox should be monitored for fluid balance and serum electrolytes to avoid fluid overload or electrolyte abnormalities.
- Patients taking lumoxiti 1 mg injection are advised to maintain adequate hydration throughout treatment.
- Patients with the therapy of lumoxiti should be monitored for weight and blood pressure prior to each infusion during treatment.
- Patients receiving lumoxiti dose must be monitored for renal function prior to each and every infusion throughout treatment.
- Nursing women with lumoxiti injection are advised to avoid breastfeeding while on receiving this medication.
